Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
Description
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after
